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Edited by S. KhorasanizadehAbstractPeroxisome proliferator-activated receptors (PPARs) are members of a superfamily of nuclear transcription
factors. They are involved in mediating numerous physiological effects in humans, including glucose and lipid
metabolism. PPARα ligands effectively treat dyslipidemia and have significant antiinflammatory and anti-
atherosclerotic activities. These effects and their ligand-dependent activity make nuclear receptors obvious
targets for drug design. Here, we present the structure of the human PPARα in complex with WY14643, a
member of fibrate class of drug, and a widely used PPAR activator. The crystal structure of this complex
suggests that WY14643 induces activation of PPARα in an unusual bipartite mechanism involving
conventional direct helix 12 stabilization and an alternative mode that involves a second ligand in the pocket.
We present structural observations, molecular dynamics and activity assays that support the importance of
the second site in WY14643 action. The unique binding mode of WY14643 reveals a new pattern of nuclear
receptor ligand recognition and suggests a novel basis for ligand design, offering clues for improving the
binding affinity and selectivity of ligand. We show that binding of WY14643 to PPARα was associated with
antiinflammatory disease in a human corneal cell model, suggesting possible applications for PPARα ligands.
© 2013 Elsevier Ltd. All rights reserved.Introduction
The peroxisome proliferator-activated receptors
(PPARs) are members of the nuclear receptor
superfamily, a group of ligand-inducible transcription
factors1 involved in the regulation of important and
diverse biological processes.2 They share a com-
mon structural organization, composed of a variable
N-terminal domain harboring a ligand-independent
activation function, a conserved DNA-binding do-
main (DBD) and a C-terminal ligand-binding domain
(LBD), which contains the ligand-dependent activa-
tion function 2 (AF-2).3 Apart from ligand recognition0022-2836/$ - see front matter © 2013 Elsevier Ltd. All rights reserveand binding, the LBD has additional functions such
as (i) regulating interactions with cofactors involved
in signal transduction during transcription and (ii)
binding to homodimerization or heterodimerization
partners.4,5
PPARα is one of three PPAR subtypes (PPARα,
PPARβ/δ and PPARγ), each of which exhibit distinct
tissue expression patterns and regulate diverse
biological functions, mediated by activation upon
binding of their respective ligands.6,7 PPARα is
predominantly expressed in the liver and, to a lesser
extent, in other cell types, including macrophages,
smooth muscle and endothelial cells. In these cells,d. J. Mol. Biol. (2013) 425, 2878–2893
Table 1. Data collection and refinement statistics
PPARα + WY14643
Data collection
Space group P212121
Unit cell dimensions (Å) 62.39, 62.68, 180.05
Resolution (Å) 36.56–2.51 (2.65–2.51)
Number of frames 370
Number of unique reflections 22,365
Δφ (°) 0.25
Mosaicity 0.66
Multiplicity 3.6 (3.5)
Completeness (%) 89.9 (98.7)
Rmerge
a 0.104 (0.497)
I/σ(I) 7.7 (2.1)
Refinement
Reflections 22,323
Rwork/Rfree
b (%) 17.31/21.57
Number of atoms
Protein (two molecules) 4092
Ligands (four molecules) 84
Water 62
B-factors
Protein (two molecules) 47.11
Ligands (four molecules) 48.57
Water 37.02
RMSD
Bond lengths (Å) 0.011
Bond angles (°) 1.350
Ramachandran outliers 0
Values in parentheses refer to the outer shell (2.05–1.95 Å).
a Rmerge = ∑hkl∑ i|Ii(hkl) − 〈I(hkl)〉|/∑hkl∑ i|Ii(hkl), where 〈I(hkl)〉
is the mean I(hkl) over symmetry-equivalent reflections.
b Rfactor/Rfree = ∑hkl|Fobs − Fcalc|/∑hkl|Fobs|, where Fobs and
Fcalc are the observed and calculated structure factors,
respectively. Rfree was calculated using 5% of the total
reflections, which were chosen randomly and omitted from the
refinement.
2879Molecular Mechanism and Mode of Ligand RecognitionPPARα plays a critical role in lipid metabolism
including β-oxidation of fatty acids and energy
homeostasis.8 Additionally, it has antiinflammatory
and anti-thrombotic actions.9,10
Many synthetic and natural PPAR ligands have
been identified,11 and three-dimensional structures
of ligands bound to this receptor class provided some
understanding of the structural basis for the mode of
action.12 Activation of PPARα by agonist ligands
triggers conformational changes in PPARα—includ-
ing stabilization of the extreme C-terminal H12 (AF-2
helix) in an active position—and enhances hetero-
dimerization with the retinoid X receptor,13 promoting
recruitment of nuclear receptor coactivators and
ultimately gene transcription.14,15
Less clear are determinants that influence affinity of
ligands for PPARα. Several fibrates—that are PPARα
agonists—are used to treat dyslipidemia and
hypertriglyceridemia16 or combined with other drugs
in antidiabetic therapies.17 These, however, only
exhibit weak affinities for PPARα, and there is interest
in new fibrates or fibrate analogs with improved
potency and selectivity for PPARα.18 Pirinixic acid
(also known as WY14643), a fibrate analog that was
used as an anti-hypercholesterolemic agent19 and
responsible for promoting peroxisome proliferation,20
is a potent and selective PPARα ligand.21 Despite its
wide-ranging use as a research tool for studies of
PPARα, its binding mode and reasons for improved
affinity have not been resolved.
PPARαalso regulates inflammatory responses.22,23
PPARα ligands display potential antiinflammatory
properties in atherogenesis and hepatitis.24 In ocular
tissue, chronic inflammation resulting from corneal
epithelial injury and/or infection can result in loss of
tissue transparency and compromised vision.25 At
present, there has been no evaluation of PPARα
ligand effects in corneal inflammation models. Recent
studies have demonstrated that WY14643 may be a
pro-inflammatory agent rather than antiinflammatory,
possibly preventing therapeutic application in
ophthalmology.26 Furthermore, in rabbit corneal
epithelium, WY14643 is involved in regulation of
hypoxia-induced inflammation by lowering of cellular
GSH levels.27 Further analyses are necessary to
discern the viability of PPARα agonists as ophthalmic
antiinflammatory agents.
In this paper, we present a crystal structure of
PPARα LBD complexed with WY14643, refined to a
resolution up to 2.5 Å. This structure shows that
ligand interacts with H12, which supports the agonist
behavior of WY14643 and conforms with the classic
activation hypothesis.28 Unexpectedly, a second
molecule of WY14643 occupies a different position
in the ligand binding pocket. Functional analysis,
combined with site-directed mutagenesis and molec-
ular dynamics (MD) simulations, suggests a biological
role for this second binding site. We investigated the
effect of WY14643 in expression of a representativepro-inflammatory cytokine (IL-6) and a chemoattrac-
tant (IL-8) in corneal epithelial cells in response to
hypertonic stress shown to induce inflammation in
vivo and in vitro. WY14643 inhibition of stress-
induced IL-6 and IL-8 expression points to the
possibility that WY14643 may have therapeutic
value in corneal inflammation in a clinical setting.Results
Crystal structure shows two molecules of
WY14643 anchored to PPARα LBD
WY14643 is widely known as a potent PPARα
agonist. To gain further insight into its binding mode,
we co-crystallized WY14643 with the human PPARα
LBD and solved the structure with a resolution up to
2.5 Å, sufficient for building protein and ligand
atomic models. The PHENIX.XTRIAGE program29
identified twinning in the data set with a fraction of
39% and k, h, − l as a twinning operator. This
information was used during the refinement process.
2880 Molecular Mechanism and Mode of Ligand RecognitionThe final model consists of two monomers of
hPPARα LBD in the asymmetric unit (encompassing
the amino acid residues from T200 to M467), four
molecules of the ligand WY14643 and 62 water
molecules. All protein residues were found in
allowed regions of the Ramachandran plot, and the
validation parameters exhibited the quality of final
models. Refinement statistics are given in Table 1.
Both macromolecular chains displayed an overall
fold in agreement with that of other LBD nuclear
receptor structures.18,30,31 They are mainly com-
posed of helices, arranged into a three-layered
sandwich, with the C-terminal AF-2 helix (H12)
positioned in the active conformation, consistent
with the agonist nature of the WY14643 ligand
(Fig. 1a).
The protein–ligand interactions observed in chains
A and B were basically the same, with two molecules
of WY14643 bound to each LBD. Consequently, the
two complexes present in the crystal asymmetric unit
will be treated hereafter as a generic model (Fig. 1a).
This is the first PPARα solved structure showing two
molecules within the ligand binding pocket. One ofFig. 1. hPPARα LBD crystal structure bound to two WY146
first and second sites. Both WY14643 molecules fitted int
methodology by PHENIX program. (b) Details of interactions
interactions with the polar side chains, including Y464, which re
helix 12. (c) Ligand and residue interactions occurring in the n
bridge network between important protein regions. Black broke
residues involved in hydrophobic interactions.the WY14643 molecules occupies standard PPARα
agonist position, performing polar and hydrophobic
contacts with the protein. Residues S280 (H3), Y314
(H5), H440 (H11) and Y464 (H12) form a well-
recognized hydrogen-bonding network with the
ligand carboxylic acid (Fig. 1b). In addition to these
standard carboxylate interactions with the upper part
of the PPARα binding pocket, WY14643 also makes
several hydrophobic contacts with the lower part of
the pocket (Fig. 1b), involving residues C276, T279,
I317 and M330. As identified for other PPAR
agonists,32 the hydrogen bond involving Y464 is
very important for maintaining the protein active
conformation; Y464 is located on the inner surface of
the AF-2 helix (H12) and the closed conformation of
the AF-2 helix is crucial for regulation of coactivator
recruitment.28
The second WY14643 binds to a secondary site
positioned between H2′ and H3. This region is called
Ω-loop; it is usually poorly structured and is thought
to be a very flexible region of LBD but appeared very
well ordered here. This second ligand is primarily
stabilized by nonpolar interactions with I241, L24743 molecules. (a) LBD receptor indicating the region of the
o the electron density map calculated using omit map
in the first site. The ligand head carboxyl group making
sult in the PPAR LBD conventional active conformations of
ewly identified second site and residues involved in a salt
n lines represent hydrogen bonds and dotted circles denote
2881Molecular Mechanism and Mode of Ligand Recognition(H2′), V255, I263, R271 (H3), I272 (H3), H274 (H3)
and C275 (H3), which contact the fused heterocyclic
rings. Another contributor to stabilization are salt
bridges between (i) the nitrogen located in the ligand
central region and E251 (H2′) and (ii) between the
carboxylic group of the ligand and the residues K266
(Ω-loop) and H274 (H3) (Fig. 1c). These basic
residues can also interact with D453 (loop H11–
H12), as suggested by the MD simulations dis-
cussed later, and form a salt bridge network, which
connects the Ω-loop, H3 and the H11–H12 loop.
Y314 is likely to promote PPARα selectivity
of WY14643
WY14643 binds to human PPARα receptor with
high affinity and selectivity.24,33 The ligand selectiv-
ity for PPARα was confirmed in dose–response
curves obtained from cell-based assays with the
three PPAR subtypes (Fig. 2). Consistent with
previous observations,34–36 WY14643 displayed
higher potency in activating PPARα with an EC50
value of 5.38 μM. On the other hand, the PPARβ and
PPARγ curves did not reach a plateau level, which
precluded calculation of ligand potency with these
subtypes (PPARδ/β EC50 = 26 mM and PPARγ
EC50 = 17 mM) (Fig. 2a).
To identify possible molecular determinants of
WY14643 selectivity, we set out to define unique
PPARα amino acids that might be involved in ligand
contact among residues that are conserved between
all three PPARs.31 To do this, we carried out a
comparison of the three-dimensional structures of
the subtypes by superposition of crystal structures
[Protein Data Bank (PDB) IDs 3ET2 (PPARβ) andFig. 2. The transcription activity of WY14643 tested toward th
are showed in the concentration–response curves and the liga
assays were performed in three replicates and were normalize
structures of PPARα + WY14643, PPARβ (PDB ID 3ET2)
substitution of αY314 (dark gray) by βH287 (gray) and γH3233ET0 (PPARγ)] and alignment of their backbones.
Among residues involved in polar contacts with the
first ligand molecule, αY314 is replaced by βH287
and γH323 (Fig. 2b). This single amino acid
substitution is also responsible for the selectivity for
other ligands.31,37 No significant PPAR subtype
differences in amino acids involved in contact with
the second ligand were observed.
αY314 and ligand oxygen atom contacts further
stabilized the ligand into the PPARα binding site. A
possible role for αY314 in PPARα selective binding
of WY14643 is corroborated by previous structure–
activity relationship studies, which showed that bulky
aromatic residues attached to α-position of the
carboxylic group of WY14643 reduced PPARα
selectivity and increased PPARγ binding.38 The
described change in preference of PPARγ for
compounds with bulky α-residues can be similarly
explained by the same residue substitution cited
above (αY314–γH323).31 In the PPARα pocket,
tyrosine occupies more space and impairs the
accommodation of large substituents. Smaller li-
gands, however, are able to form tighter interactions
with PPARα than in the larger PPARγ pocket.
Variations in the pocket topology and hydrophobicity
may also contribute to selectivity; the PPARα isotype
pocket is more hydrophobic than other PPARs,31
and this may account for enhanced interactions
between the hydrophobic tail of WY14643 and
PPARα.
The second site is important for function
The presence of a second ligand molecule at an
unsuspected position in the PPARα LBD raisesree PPAR LBD subtypes in GAL4-based assays. (a) Tests
nd activation expressed as a relative luciferase activity. All
d by Renilla luciferase activity. (b) Superposition of crystal
and PPARγ (PDB ID 3ET0). This analysis showed the
(light gray), suggesting its role in the isotype α selectivity.
Table 2. Potency of WY14643 and GW7647 (control)
toward PPARα and mutants, as determined in GAL4-
based assays
Clone of PPARα EC50 (M) (WY14643) EC50 (M) (GW7647)
Wild type 5.38 × 10−6 8.13 × 10−8
V255A/I263A ~0.73 (ambiguous) 5.27 × 10−8
Values were calculated from three independent experiments each
performed in triplicate.
2882 Molecular Mechanism and Mode of Ligand Recognitionquestions about second-site functionality: does the
second ligand merely stabilize PPARα in the
crystalline form or is this ligand also necessary for
generating conformational changes required for the
full PPARα activity? One indication of second-site
functionality is that this region can also be partially
occupied by other high-affinity synthetic PPARα
ligands 18,30–32,39–43 and partial agonists in
PPARγ.44–46 PPARγ partial agonists that occupy
this position cause conformational changes that
produce a decrease in the helix 12 dynamics and
stabilize the interaction with coactivators.
We carried out site-directed mutagenesis to
explore the function of the receptor second binding
site. The selected mutation (V255A/I263A) should
disrupt ligand binding to his region, without altering
the first site by decreasing ligand hydrophobic
contacts (Fig. 3a). Effects of mutations upon
WY14643 activity were compared with that of the
high-affinity synthetic ligand GW7647, which served
as a positive control of PPARα functionality and
should interact only with the first site. Table 2 shows
differences in EC50 values for native and mutant
protein constructs. The PPARα V255A/I263Amutant
decreased PPARα sensitivity to WY14643 (Fig. 3b).
It was not possible to extract the EC50 value for this
ligand since the titration curves do not reach a
plateau. On the other hand, these mutations did not
affect the activity of GW7647 whose EC50 value was
practically the same for both native and mutated
PPARα. This invariance shows that the mutant
protein remained active because its folding wasFig. 3. Double mutation (V255A/I263A) effect on the PPARα
that were mutated to alanine. Both residues are located in
WY14643 (black lines) and GW7647 (used as a control; gray
mutated (broken line) PPARα in a GAL4-based assay. Results
were performed in three replicates and were normalized byRen
efficiency.unaffected and suggests that the second site is
required for full WY14643 activity.
WY14643 interactions in the second site
promote a local stabilization of the LBD and
AF-2 region
Binding of WY14643 to the second binding site
could activate PPARα by stabilizing the H12 in the
active conformation without any direct contact with
the helix, analogous to PPARγ partial agonists.44–46
Additional interactions in the second site between
WY14643 and residues near H12 were detected in
the crystallographic model. H274 (H3) and K266 (Ω-
loop) form salt bridges with the carboxylate group of
the second WY14643 molecule. These residues are
also close to D453 (loop H11–H12).
The roles of H264, K266 and D453 on WY14643
binding and activation were investigated via site-
directed mutagenesis followed by transactivationactivity against WY14643. (a) The V255 and I263 residues
the protein second site. (b) The transcription activity of
lines) were tested toward wild-type (continuous line) and
are expressed as a relative luciferase activity. All assays
illa luciferase activity to remove differences in transfections
Table 3. Potency of WY14643 and GW7647 (control)
toward PPARα and mutants involving electrostatic
interactions cluster, as determined in GAL4-based assays
Clone of PPARα EC50 (M) (WY14643) EC50 (M) (GW7647)
Wild type 0.67 × 10−6 2.32 × 10−8
H264A 3.31 × 10−6 4.38 × 10−8
K266A 2.20 × 10−6 3.92 × 10−8
D453A 2.18 × 10−6 5.58 × 10−8
Values were calculated from experiments performed in triplicate.
2883Molecular Mechanism and Mode of Ligand Recognitionassays. Effects in the GW7647 activity were also
investigated as a control to determine whether
mutations influence actions of a ligand that only
binds in the first site. All the selected residues were
mutated to alanine in order to prevent the formation
of electrostatic interactions. While mutations did not
significantly affect efficacy of either ligand at high
doses, they did reduce the potency of both
WY14643 and GW7647, as observed in a shift in
EC50 values (Table 3). Interestingly, however, the
shift in EC50 values was larger with WY14643, which
binds at the second site near the charge cluster, than
with GW7647. Thus, the charge cluster is requiredFig. 4. Influence of the second WY14643 molecule on the m
mobilities are shown as aligned snapshots from the MD traject
(RMSF ≤ 0.5 Å), green is intermediate mobility (RMSF = 1.75
suggest that PPARα LBD is stabilized by the presence of an ext
in the presence of a single ligand (b). Major mobility differences
H2′ (P site) and at the H12.for optimal ligand activation, probably because
differences in the hydrophobic packing of Ω-loop
and loop H11–H12 could affect H12 dynamics and
inhibit ligand activation. However, the fact that
charged residues play a more important role with
WY14643 suggests that these interactions could
become more important for ligands that bind at the
second site.
To confirm this hypothesis, we performed two sets
of MD simulations of the PPARα LBD: a set of six
independent MD simulations with two WY14643
molecules bound to PPARα LBD and another set of
six independent MD simulations with a single
WY14643 molecule bound to the first site of
PPARα LBD to test whether there were differences
in mobility and/or stability of PPARα LBD structure
with two ligands or one ligand.
Figure 4 shows aligned snapshots extracted from
the simulations and the corresponding root-mean-
square fluctuation (RMSF) as indicators of the
mobility of the PPARα LBD. The alignment proce-
dure is described elsewhere.47,48 The presence of
WY14643 at the second site strongly stabilizes the
Ω-loop and the loop between H2 and H2′ (Fig. 4a) as
compared to the presence of a single ligand at theobility (RMSF of Cα atoms) of PPARα LBD backbone. The
ories and also as a color scale in which blue is low mobility
Å) and red is high mobility (RMSF ≥ 3.0 Å). These results
ra ligand at the second site (a) as compared to PPARα LBD
are observed at the Ω-loop, at the loop connecting H2 and
Fig. 5. H12,Ω-loop and P site mobilities computed for the essential trajectories. (a) RMSD distribution of H12 computed
with respect to its average structure, showing the lower mobility of this helix in the presence of two ligands (blue) as
compared to that in the presence of a single ligand (red). (b) RMSD of the H12 plotted against the RMSD values of Ω-loop
and P site computed for the essential trajectories. There is a positive linear correlation between the mobilities of these
regions, as confirmed by the correlation coefficients (R) resulting from linear regression analysis. These coefficients
systematically increase in the presence of two ligands (blue) in comparison to just one ligand (red). There is no evident
correlation between the Ω-loop and the P site in the presence of a single ligand (R = 0.24), but they appear to become
slightly correlated in the presence of the second ligand (R = 0.55) (data not shown).
2884 Molecular Mechanism and Mode of Ligand Recognitionfirst binding site (Fig. 4b). The loop connecting H2
and H2′, known for being susceptible to posttrans-
lational modification in PPARs,49 will hereafter be
referred to as the P site. In addition to theΩ-loop and
the P site, H12 was mildly stabilized by the second
ligand, as indicated by the root-mean-square devi-
ation (RMSD) distribution in Fig. 5a, which is slightly
narrower and shifted to smaller values in theFig. 6. The charge cluster formed by residues K266, H274 a
preceding H12 and the H3. For both systems (one or two liga
within the charge cluster, whose frequency is shown in (a). In t
charge cluster is stabilized as compared to the single ligand c
charge cluster is stabilized by interactions that involve the sec
absence (c).presence of two ligands. The two-dimensional plots
of the RMSD values of H12 versus the RMSD of the
Ω-loop and the P site (Fig. 5b) indicate that the
mobility of H12 correlates directly with the mobility of
these two other regions; correlations occur in both
systems but are systematically enhanced by the
second ligand despite the narrower range of RMSD
values with two ligands. No significant changes werend D453 acts as a bridge connecting the Ω-loop, the loop
nds), three different modes of interaction were observed
he system containing a second ligand molecule (blue), the
ase (red). As shown by the representative structures, the
ond ligand itself (b) and, thus, cannot be fully formed in its
2885Molecular Mechanism and Mode of Ligand Recognitionobserved in the structure or dynamics of other
regions of PPARα LBD, supporting the idea that
the second WY14643 only strongly stabilizes the Ω-
loop and the P site and indirectly promotes a more
subtle stabilization of H12.
Close inspection of the MD trajectories indicates
that stabilization of Ω-loop and H12, as well as the
correlation between their mobilities, can be partially
explained by electrostatic interactions involving
H274 (H3), K266 (Ω-loop) and D453 (loop H11–
H12). In both systems (with one or two ligands),
these residues may form similar salt bridges that
comprise the charge cluster connecting the Ω-loop,
the loop preceding the H12 and the H3 (Fig. 6). In the
presence of a single ligand (Fig. 6a, lower panel, and
c), at least three different interaction modes within
this charge cluster were identified. Modes I′ and II′
are characterized by average interaction energies of
−152.2 ± 5.8 kcal/mol (44% of the simulation time)
and −115.3 ± 12.5 kcal/mol (52% of simulation
time), respectively, and both connect the Ω-loop to
the loop preceding H12. Mode III′ (no bridge) is
enthalpically less favorable, with an average energy
of only −53.1 ± 13.4 kcal/mol. Mode III′ appears
only 4% of the simulation time.
Electrostatic interactions in the second binding site
are more frequently formed in the presence of the
second ligand, with the ligand itself participating in
the charge cluster (Fig. 6a, top panel, and b).
Interaction modes are similar to those occurring in
the presence of a single ligand but are more stable
because of the additional interactions provided by
the second ligand itself. Mode I that represents the
most stable form of the charge cluster—with four
different interactions occurring simultaneously—is
also the most frequently sampled mode, appearing
in 52% of the simulation time. Interestingly, the
interactions occurring in mode I connect the Ω-loop
not only to the loop preceding H12 but also to H3.
Mode II appears less frequently (22% of the
simulation time), but like mode I, it displays in-
teractions that connect the Ω-loop to the loop
preceding H12. Mode III (29%) resembles mode III′
since it does not directly connect the Ω-loop to theloop preceding H12. However, mode III displays two
interactions connecting the highly mobile Ω-loop and
H3, as in mode I.
Among these interactions, we propose that the
K266–D453 salt bridge is at least partially respon-
sible for the observed correlations between mobil-
ities of the Ω-loop and H12 since it provides direct
contact between this loop and the loop preceding
H12. Moreover, this interaction is frequently formed
in both systems (modes I, I′, II and II′). Alone,
however, this salt bridge might enhance H12 mobility
by connecting it to the highly mobile Ω-loop. It may,
therefore, account for the correlation between these
two regions but not for ligand-induced stabilization of
H12 observed during the course of the simulations.
Instead, we attribute the additional stabilization of
H12 to interactions that directly or indirectly connect
the highly mobile Ω-loop to H3, one of the most rigid
regions of PPARα LBD, as already shown in Fig. 4.
Apart from the previously mentioned hydrophobic
contacts, there are important second ligand-mediat-
ed electrostatic interactions between Ω-loop and H3
exemplified by modes I and III that contribute to H12
stabilization.
Overall, mutagenesis experiments and dynamic
simulations suggest that the salt bridge connecting
theΩ-loop to the loop preceding the H12 is important
for correlating these two regions, but this correlation
only translates into H12 stabilization if the Ω-loop is
stabilized by further second ligand-dependent in-
teractions with H3.
WY14643 induced dose-dependent decrease in
IL-6 and IL-8
We compared the antiinflammatory activity of
WY14643 to that of the PPARα antagonist,
GW6471, in a human corneal cell wound-healing
model, which simulates exposure to hypertonic tears
encountered in some types of dry eye disease.
Figure 7 shows that the human corneal epithelial
cells (HCEC) cell line expresses PPARα protein.
Antibody selectivity was validated by the fact that
omission of the primary antibody eliminated staining.Fig. 7. Immunohistochemistry
confirms the presence of PPARα
expression in HCEC. Omission of
primary antibody confirms selectiv-
ity of anti PPARα antibody. Nuclei
were stained with 4′,6-diamidino-2-
phenylindole.
Fig. 8. Changes in IL-6 and IL-8 expression induced by modulation of PPARα activity under hypertonic (i.e.,
450 mOsm) and isotonic (i.e., 300 mOsm) conditions. Under isotonic conditions, HCEC were exposed for 24 h to different
doses of (a) PPARα agonist WY14643 and (b) PPARα antagonist GW6471. (c) Under hypertonic conditions, HCEC were
exposed to different doses of WY14643 and GW6471. Subsequent to incubation, medium was collected and IL-6 and IL-
8 levels were assayed by enzyme-linked immunosorbent assay. Data were normalized based on cell density through
protein content using a modified Lowry procedure. Each experiment was repeated three times and performed in triplicate
on each occasion. Data are expressed as means ± SEM.
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stress (450 mOsm hypertonic medium) identified in
the tears of some dry eye patients. These individuals
have elevated expression of two cytokine bio-
markers (IL-6 and IL-8) that are also elicited in
vitro.50 Such rises contribute ocular inflammation in
dry eye patients with aqueous deficient tears.51
Under isotonic conditions, the results shown in
Fig. 8a indicate that, at doses near the EC50 value for
WY14643 (i.e., 5.4 μM), IL-6/IL-8 levels were in-
duced to similar levels obtained from those induced
by the hypertonic stress (Fig. 8c). However, at the
dose needed to maximally activate PPARα, IL-6/IL-
8 levels were lowered to near control levels
measured in a 300-mOsm isotonic medium. In
contrast to this biphasic effect, the PPARα antago-
nist (GW6471) increased IL-6/IL-8 levels in a strictly
dose dependent fashion (Fig. 8b). In NaCl supple-
mented hypertonic (450 mOsm) Dulbecco's modi-
fied Eagle's medium (DMEM)/F12 medium, IL-6/IL-
8 levels rose about 2-fold whereas pre-incubation
with WY14643 (120 μM) suppressed such rises to
near baseline levels measured under isotonic
conditions (Fig. 8c). Such suppression was not
cytotoxic since the IL-6/IL-8 levels measured, in the
presence of WY14643, during exposure to the
hypertonic stress were the same as those under
the isotonic condition. Figure 8b shows that 200 μM
GW6471 enhanced IL-6/IL-8 release by 1.5-fold
under both isotonic and hypertonic conditions.
These increases in IL-6/IL-8 caused by GW6471
were partially suppressed by pre-incubation with
WY14643 (Fig. 8c). Together, opposing effects of
WY14643 and GW6471 on IL-6 and IL-8 show that
PPARα regulates cytokine expression in HCEC
similar to another study employing primary HCEC.26Discussion
WY14643 is a synthetic PPARα ligand that
resembles clinically useful fibrate drugs and is
often used as a positive control for PPARα activa-
tion. Nevertheless, the molecular elements involved
in protein–ligand recognition by PPARα were not
known. Here, we report a structure of the PPARα in
complex with WY14643, which suggests that this
fibrate analog induces activation through an unusual
bipartite mechanism involving conventional direct
H12 stabilization and an alternative mode that
involves a second ligand in the pocket.
The first WY14643 ligand copy directly interacts
with helix 12, like many other PPAR agonists, and
also forms similar interactions with polar residues
that are important for stabilizing the majority of
known ligands for this protein target. These in-
teractions include the direct contact with Y473
localized in AF-2, which promotes stabilization of
the active protein conformation. This configurationalso provides additional stabilization of the ligand
hydrophobic tail by nonpolar residues in the inner
region of the first site. A close-up view of super-
imposed PPAR subtype structures around the first
site reveals PPARα-specific amino acid contacts
with the first copy that explain why WY14643
preferentially activates PPARα versus other sub-
types. This agrees with previous studies revealing
the importance of a single residue substitution within
this region of the pocket in modulating ligand
selectivity.52,53
Crystallographic model refinement also identified a
second WY14643 molecule within the pocket. Two
lines of evidence suggest that this second binding
site is important for function. First, mutation analysis
of residues that contact the second ligand copy
(V255 and I263), but not the first, is required for
optimal activity of WY14643 and does not interfere
with activity of another PPARα ligand (GW7647) that
only occupies the first site. Second, MD simulations
suggest that the second ligand strongly stabilizes the
highly mobile Ω-loop by the formation of a charge
cluster that also involves the ligand itself, and this
event appears to be directly correlated with a more
subtle stabilization of H12 and the P site. Thus, we
suggest that the second site locally stabilizes
important regions of the protein that indirectly
influence H12.
Similar mechanisms have been proposed to
explain actions of PPARγ partial agonists—ligands
that lack direct contact with H12 but can still activate
PPARγ to a lesser extent—and also bind at a similar
location to the second WY14643 site. For these
ligands, recent experimental evidence point to
alternative mechanisms that do not involve the
stabilization of H12, but rather the stabilization of
H3 and the β-sheets54 and/or modifications in the
structure and dynamics of the flexible region known
as Ω-loop.55–57 These data suggest that, although
the stabilization of alternative regions might not be
required for normal activation by ligands that contact
H12, it is still important for activation of PPARs by
ligands that bind near the β-sheets/Ω-loop and do
not interact directly with H12. It is also interesting to
propose that PPARα activity modulation by other
fibrate analogs might involve partial occupation of
the second binding pocket by ligand hydrophobic
tails. Alterations in the position of hydrophobic
interactions between fibrate extended poly-aryl
group and hydrophobic residues within the pocket
account for ligand potency variations.10
We recognize that our proposed model would be
strengthened by direct determination of ligand
stoichiometry and affinity for wild-type PPARα and
the PPARα second-site mutant (V255A/I263A) by
isothermal titration calorimetry. In fact, we attempted
these studies, but technical difficulties prevented
accurate measurements of ligand binding properties.
Specifically, only 5% of our PPARα LBD prepara-
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ligand association was extremely rapid with low
apparent stoichiometry. We attribute this observa-
tion to an extremely high prevalence of bacterial fatty
acids within the PPARα ligand binding pocket that
prevent binding of other ligands, and we have
confirmed the presence of these ligands (predomi-
nantly myristic, palmitic and stearic acids) by mass
spectroscopic analysis of purified PPARα LBD and
crystallization of PPARα in the absence of exoge-
nous ligand (data not shown). We attempted to
remove these fatty acids with a variety of chromato-
graphic techniques, without success, and to crystal-
lize the PPARα V255A/I263A mutant to see whether
WY14643 occupied the first site, again without
success. While it therefore remains possible that
our V255A/I263A mutation impairs PPARα function
via effects on overall protein stability and not direct
effects upon ligand binding at the second site, two
lines of evidence argue against this interpretation.
First, activity of a ligand that only binds at the first site
(GW7647) is completely unaffected by this mutation.
Second, WY14643 remains competent to weakly
activate PPARα V255A/I263A and we favor the
notion that this reflects activity of ligand bound to the
first site alone.
Given that several MD studies with RAR,58
RXR,59 TR47,60,61 and PPARs62 suggested that
the Ω-loop constitutes a ligand entry/exit pathway,
one may argue that the PPARα V255A/I263A
mutation could impair general ligand association
processes rather than specifically blocking
WY14643 interactions with the second site. How-
ever, such a blockage should have similar affect in
the association of the ligand GW7647, which
displayed full activity in the context of the double-
mutated PPARα. Moreover, a decrease in the
ligand association rates would be accompanied by
a similar decrease in the dissociation rates.
Therefore, the putative impairment of ligand asso-
ciation would reduce the activity to the same
extend that the impaired dissociation would in-
crease its activity by increasing its residence time
in the binding pocket.
Future studies could be performed to refine the
identity of the sites within the LBD that need to be
ligand bound in order to further optimize binding
affinity and functional PPARγ activation. This could
be performed through consideration of a larger
binding area to be filled, which might result in better
ligand affinity and improvement of protein activation.
Alternatively, the LBD region could also be interro-
gated to design novel partial agonists for the purpose
of decreasing potential disadvantages of strong
agonists. Such an approach has led to the identifi-
cation of targets on PPARγ for activation by partial
agonists.
We have shown that the PPARα agonist
WY14643 exhibits antiinflammatory activity incorneal cells subjected to hypertonic stress. Thus,
we believe that drug stimulation of PPARα activity
may be a viable method to reduce inflammation in
dry eye disease. We must approach this idea with
caution. Another group investigated effects of
PPARα agonists upon inflammation in ocular cells
and observed enhancement of IL-6 production, and
we obtained similar results with subsaturating
WY14643 levels in hypotonic medium. However,
stimulatory effects of lower levels of WY14643
were reversed at higher WY14643 concentrations
and we also observed strong suppression of IL-6
ad IL-8 production in hypertonic medium. It is likely
that the inhibitory effects of WY14643 upon IL-6
and IL-8 production that we observed are PPARα
dependent because they were reversed by the
PPARα antagonist GW6471. We believe that the
likely explanation for apparent discrepancies be-
tween our results and those of previous studies lies
in the mode of induction; we used hypertonic
stress to induce inflammation and applied
WY14643 later whereas the other group co-treated
cells with IL-1β and PPARα agonist. It is also
interesting to speculate that biphasic effects of
WY14643 upon inflammatory response could be
related to stoichiometry of ligand in the pocket,
although we recognize that this idea is far from
proven. It will be important to test activity of
existing and novel PPARα agonists in a variety of
assays to understand how these compounds affect
inflammation and whether binding of ligands at
different pocket sites could exert differential effects
on inflammation.
Based on aforementioned approaches, we sur-
mise that binding of a second WY14643 molecule in
another region of the protein pocket plays a critical
role in maintaining potent PPARα functional activity.
Additionally, this unique binding mode thus provides
a new mode of ligand recognition and structural
basis of ligand design, offering clues for improving
the binding affinity and selectivity of ligand to the
target protein.
Experimental Procedures
Expression and purification
The LBD of hPPARα (amino acids 194–468) was
expressed in Escherichia coli strain BL21 DE3 as an N-
terminal histidine tag from the pET28a expression vector,
where the protein was cloned. Transformed bacteria were
cultured in LB medium with the addition of 50 μg/mL
kanamycin at 37 °C. Protein overexpression was induced
by addition of 1 mM isopropyl β-D-1-thiogalactopyrano-
side, and the temperature was shifted to 18 °C. Cells were
harvested 12 h after induction and resuspended in 30 mL
buffer A [50 mM sodium phosphate buffer (pH 7.5),
300 mM sodium chloride (NaCl) and 10% glycerol]
supplemented with 10 mM β-mercaptoethanol, 10 mM
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per liter of culture. Then, the lysate was sonicated and
clarified by centrifugation, and the supernatant was loaded
onto a Talon Metal Affinity Resin (BD Biosciences
Clontech, Palo Alto, CA). After extensive washing of
column with buffer A, hPPARα LBD was eluted with buffer
B [50 mM sodium phosphate buffer (pH 7.5), 300 mM
NaCl, 10% glycerol, 300 mM imidazole and 10 mM β-
mercaptoethanol]. A second step of purification was
included, using gel-filtration chromatography on a HiLoad
16/60 Superdex 75 column (GE Healthcare) equilibrated
with buffer C [20 mM Hepes (pH 8.0), 150 mM NaCl, 5%
glycerol and 1 mM dithiothreitol]. Fractions containing the
protein of interest were pooled, the N-terminal His tag was
cleaved with thrombin protease (0.5 U/mg of protein) and
the purity of hPPARα LBD (N95%) was analyzed by
Coomassie Blue Stained SDS-PAGE.
Crystallization and data collection
Crystals of hPPARα LBD + WY14643 complex were
obtained by co-crystallization. Concentrated samples of
purified protein (hPPARα LBD at 10 mg/mL) were mixed
with 1 mM WY14643 in order to form the complexes. The
initial screening of crystallization conditions was per-
formed using a HoneyBee crystallization robot 931
(Genomic Solutions), and the conditions that seemed
promising were reproduced using hanging-drop vapor-
diffusion method in the traditional manual setup in which
1-μL hPPARα LBD + WY14643 samples were mixed with
an equal volume of reservoir solution and equilibrated
against 500-μL reservoir solution. Crystals were obtained
in a few days during exposure to a reservoir solution
whose composition was 100 mM Tris–HCl (pH 7.5) and
30% (w/v) polyethylene glycol 10,000 at 18 °C. After
briefly soaking in a cryoprotective solution [crystallization
condition with the addition of 15% (v/v) ethylene glycol],
the crystals were flash-cooled in a gaseous nitrogen
stream at 100 K and the X-ray diffraction data set was
collected at the protein crystallography MX2 beamline at
the Laboratório Nacional de Luz Síncroton (Campinas,
Brazil) using synchrotron radiation of wavelength 1.459 Å
and MAR225 mosaic detector, with an oscillation of 0.25°
per frame. Data reduction and integration were performed
using iMOSFLM63 and scaled using SCALA.64 Statistics
of data collection are given in Table 1.
Model refinement and structure determination
The structure model was constructed by molecular
replacement using the program PHASER64 and PDB ID
2REW as template. The programs PHENIX29,65 and Coot66
were used to alternately run cycles of model building and
refinement. The ligand and water molecules were included
only in the last steps of refinement. Refinement statistics are
given in the Table 1. The atomic coordinates and structure
factors of hPPARα LBD + WY14643 crystal structure
reported here were deposited in the PDB under code 4BCR.
Site-directed mutagenesis
The mutagenesis experiments were carried out accord-
ing to Batista et al. and the manufacturer's protocolprovided by QuikChange Site-Directed Mutagenesis Kit
(Stratagene).67 The mutated residues were chosen by
inspection of the crystallographic structure and introduced
by PCR in the existing vector pBIND, containing hPPARα
LBD/GAL4 DBD chimeric protein, by overlapping of
mutated primers. All mutated constructs were verified by
sequencing.
Transient co-transfection assays
Transactivation assays using luciferase gene reporter
were carried out following transient transfection of three
plasmids: pGRE-LUC (GAL4 responsive element, Firefly
luciferase reporter vector), pBIND plasmid (Promega)
containing wild type or mutants of hPPARα LBD/GAL4
DBD chimeric protein and pRL plasmid (Promega) con-
taining the Renilla luciferase gene, included as a trans-
fection and cell viability control. These plasmids were
transfected using FuGENE 6 transfection reagent (Roche),
according to the manufacturer's protocol, in the HepG2
cells (from the Cell Culture Facility at the University of
California, San Francisco) cultured in DMEM supplemen-
ted with 10% (v/v) fetal bovine serum, 4 mmol/L glutamine,
100 U/mL penicillin and 0.1 g/L streptomycin, under 95%
air and 5% CO2 at 37 °C.
68 To perform the assays, we
plated the cells in a 24-well plate (density of 1.2 × 105
cells/well) and, after 24 h of transfection, we added the
ligands to the cells at the indicated concentrations to
construct the dose–response curves. The cells were lysed
for another 24 h after the onset of stimulation using the
lysis buffer (Dual-Luciferase Report Assay System;
Promega). The constant light signal reporter gene assay
was performed in a Safire 2 luminescent counter (Tecan,
Tecan US, Durham, NC) and the relative luminescence of
Firefly luciferase activity was normalized to the Renilla
luciferase activity. Obtained data were fitted using a
sigmoidal dose–response function with corresponding
EC50 determination according to GraphPad Prism soft-
ware (version 5.0).
MD simulations
The initial configuration for the PPARα LBD complex
was obtained from the crystallographic structure reported
here. The complete simulated systems were built with
VMD (solvate and autoionize plugins)69 containing the
PPARα LBD complex, including protein, ligands and
structural water molecules, as well as solvent and
counterions for electroneutrality at the physiological
concentration (0.15 M). We used a simulation box of
dimensions 72.92 Å × 86.21 Å × 86.83 Å containing
15,300 water molecules and 22 pairs of Na+ and Cl−
ions for simulations with a single WY14643 ligand. An
extra Na+ ion was added in the simulations with two
ligands. The average thickness of the protein hydration
layer was 15 Å. The H++ server was used to set the
protonation state of the acid and alkaline residues.70
Arginines, lysines, histidines and glutamic and aspartic
acids were considered in their ionic state, with exception of
histidines H396, H406, H440 and H457, which were
considered neutral (epsilon hydrogen). Auxiliary simula-
tions were also conducted with deprotonated H274,
yielding essentially identical results as with the neutral
state of this residue.
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2.0 fs and the velocity Verlet algorithm.71 A 14-Å cutoff with
smooth switching function starting at 12 Å was used for the
van der Waals interactions, whereas electrostatic forces
were treated via the particle mesh Ewald method.72
Minimization and equilibration were performed as follows:
the energy of the systemwasminimized by 2000 conjugate
gradient steps followed by 200 ps equilibration MD
simulation in the NPT ensemble keeping all protein atoms
fixed. Fixing only theCα atoms, we performed another 2000
conjugate gradient steps and 200 ps equilibration MD
simulation. Finally, 2 ns equilibration MD simulations were
carried out without any restrictions. Temperature and
pressure were kept constant at 298 K and 1 bar with
Langevin thermostat and barostat. The damping coefficient
of Langevin thermostat was 5 ps−1. The oscillation period
and decay time of the piston in Langevin barostat was
200 fs and 100 fs, respectively. The production MD
simulations were performed after this protocol in the NPT
ensemble, lasting 6 ns.
Using this procedure, we carried out six independent
simulations for each one of the systems described as
follows: (i) PPARα LBD bound to two ligands (one in the
classical ligand binding pocket and the other in the second
binding site) and (ii) PPARα LBD bound to only one ligand
(in the classical ligand binding pocket). All simulations
were performed with NAMD 2.873 applying the CHARMM
27 force field for proteins74 and the TIP3P model for
water.75 The WY14643 molecule was parameterized
consistently with the CHARMM force field following the
protocol used for other biomolecules.76,77
Trajectory analyses, including RMSF, RMSD and
interaction energies, were performed using VMD69 and
homemade analysis programs. We also used a home-
made program to perform principal component analysis
(PCA) on the MD trajectories. Briefly, the PCA method
allows one to decompose the dynamics of the protein into
several independent (orthonormal) motions, each one
describing part of the total motion of the system.78 Apart
from providing a better understanding of the main motions
described by the protein, PCA makes it possible to
combine only the motions of higher amplitudes in a
trajectory to describe the so-called essential dynamics of
the system. We applied PCA to our set of MD trajectories,
and the resulting “essential trajectories” composed of the
first three principal components were used to interpret
some aspects of protein dynamics reported here.Immunostaining assays
SV40 HCEC kindly supplied by Araki-Sasaki were
maintained in DMEM/F-12 supplemented with 6% fetal
bovine serum, 5 ng/mL epidermal growth factor, 5 μg/mL
insulin and 40 μg/mL gentamicin in humidified 5% CO2,
95% ambient air incubator at 37 °C.79 Cells were grown to
80–90% confluence in DMEM with supplements in a 50-
mm flask (Corning). Cells were detached with 0.5% trypsin
ethylenediaminetetraacetic acid and were subcultured in
DMEM/F12 medium in a 12- or 24-well plate with
appropriate amount of medium. Cell cycle arrest was
achieved by culturing cells in serum-free and epidermal
growth factor-free DMEM/F-12 medium overnight before
optimization of cell responsiveness.HCEC were immunostaining following being fixed on ice
for 15 min with 1% paraformaldehyde–phosphate-buff-
ered saline (PBS) solution and washed three times with
Hepes Ringer solution and permeabilized with 0.1% Triton
in PBS for 20 min and then washed. Normal goat serum
(10%) was used to block nonspecific cell binding sites for
30 min. The cell monolayers were exposed overnight at
4 °C to a primary antibody (i.e., rabbit anti-PPRAα
polyclonal IgG) at a dilution of 1:200 (in 1.5% goat serum/
PBS solution). After three-time washes with Hepes Ringer
solution, the cell monolayer was incubated with a
secondary antibody (i.e., rabbit anti-PPAR anti-rabbit
IgG-TR at a dilution of 1:800 for 30 min at room
temperature). The HCEC were then loaded with a nuclear
dye, 1 μM SYTO®16, for 5 min and then washed with
Hepes Ringer solution. Images were taken with a Nikon
inverted microscope with a 60× objective lens (N.A. 1.4)
and with a Roper Scientific CCD camera and images were
processed using Photoshop 5.5 (Adobe Systems, San
Jose, CA).Enzyme-linked immunosorbent assay
IL-6 and IL-8 content was determined in the superna-
tants using enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN) according to the manufac-
turer's instructions. HCEC were plated in 12-well cell
culture plates to reach 80–90% confluence and exposed to
WY14643 or PPARα antagonist (GW6471) for 30 min
before stressing them with NaCl supplemented hypertonic
(450 mOsm) DMEM/F12 medium for 24 h. Supernatants
were harvested after centrifugation at 1000 rpm for 5 min
to remove cell debris. The supernatants were stored at −
80 °C until analysis. Protein concentration of each cell
lysate was determined by using a bicinchoninic acid
protein assay kit. The amounts of IL-6 and IL-8 in the
culture medium were normalized according to the total
amount of cellular protein lysed with 5% SDS and 0.5 N
NaOH. Results were expressed as mean picograms of IL-
6 or IL-8 per milligram of cell protein ± SEM (standard
error of themean) (n = 3). Data are expressed as mean ±
SEM. Experiments were performed in triplicate unless
otherwise indicated. Statistical significance was deter-
mined by Student's unpaired t-test. P b 0.05 was taken to
be significant unless otherwise stated.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jmb.2013.05.010
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